Drug Profile
Vidofludimus calcium - Immunic
Alternative Names: 4SC-101; IM 90838; IMU 838; SC-12267; VidoCaLatest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator 4SC
- Developer 4SC; Arizona State University; Immunic; Mayo Clinic
- Class Amides; Anti-inflammatories; Antivirals; Biphenyl compounds; Carboxylic acids; Cyclopentanes; Fluorobenzenes; Phenyl ethers; Small molecules
- Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Nuclear receptor subfamily 4 group A member 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Multiple sclerosis
- Phase II/III COVID 2019 infections
- Phase II Crohn's disease; Ulcerative colitis
- Discontinued Inflammatory bowel diseases; Primary sclerosing cholangitis; Rheumatoid arthritis; Systemic lupus erythematosus; Transplant rejection
Most Recent Events
- 20 Mar 2024 Immunic has patents pending for Vidofludimus calcium and other salt forms as well as free acid forms for treating neurodegenerative diseases in the US
- 20 Mar 2024 The US Patent and Trademark Office issues a Notice of Allowance for patent application for Vidofludimus calcium in USA
- 29 Feb 2024 Efficacy data from a phase II CALLIPER trial in Multiple sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024 (ACTRIMS-2024)